A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)

NCT07739186 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG: BL-B01D1
DRUG: PD-1/VEGF Bispecific Antibody
DRUG: Tislelizumab
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Cisplatin

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]